The DCIS and IDC‐NST subsequently acquired somatic mutations, with the acquisition of a truncating mutation in the tumor suppressor STAG2 in DCIS and an FGF12 missense mutation in IDC‐NST (Figure 3B,C). Here, STAG2 is linked to ductal breast carcinoma in situ.